AC Immune S.A.

NASDAQ:ACIU

Biotechnology

Healthcare
$2.11 +1.71%

+$0.04 today

Market cap
$214.74M
Beta
1.56
P/E (TTM)
-2.9
EPS (TTM)
-$0.67
52W Low $1.65High $4.00

Volume 0.12M

Average 0.32M

ACIU EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

AC Immune S.A.NASDAQ: ACIU

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -CHF 0.15, compared with -CHF 0.19 a year earlier. Trailing-twelve-month EPS (Basic) was -CHF 0.66.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 2 analysts of -CHF 0.38 (+46.1%) for the fiscal year ending Dec 2026, a step up from the -37.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 0.15-7.1% QoQ
Last fiscal yearDec 2025
-CHF 0.7-37.3% YoY
LTMMar 2026
-CHF 0.66-32.0% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.1%+146.5%+125.4 pp
1 year-37.3%+46.1%+83.4 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

CHF · from the income statement

Latest · FY2025
(0.70) CHF
Year-over-year change
-37.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How ACIU compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -32.0% is the 8th highest of 10, against a peer median of -3.4%.
ACIU Competitors
EPS (Basic) for ACIU and competitors
Company Period LTM YoY 3-year CAGR
MREOMereo BioPharma Group plcLTM Mar 2026-$0.22 USD+99.9%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$0.46 USD+52.9%—
ACIUAC Immune S.A.LTM Mar 2026-CHF 0.66 CHF-32.0%—
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$0.67 USD-42.8%—
CLLSCellectis S.A.LTM Mar 2026-$0.68 USD-8.4%—
ANNXAnnexon, Inc.LTM Mar 2026-$1.22 USD-3.4%—
AMRNAmarin Corporation plcLTM Mar 2026-$1.62 USD+62.1%—
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$1.95 USD-1.0%—
ANROAlto Neuroscience, Inc.LTM Mar 2026-$2.48 USD-6.4%—
SLNSilence Therapeutics plcLTM Mar 2026-$4.32 USD——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$16.98 USD-1259.1%—
Peer median (excluding ACIU) —-3.4%—

Competitors are the stored peer set for ACIU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue03.94M14.8M27.31M3.57M
Cost of Revenue0054.61M62.57M0
Gross Profit03.94M(39.81M)(35.26M)3.57M
Gross Margin—100.0%-268.9%-129.1%100.0%
Research & Development62.28M60.34M54.61M62.57M56.44M
Selling, General & Admin10.88M9.58M10.58M11.43M11.65M
Operating Expenses79.01M74.78M13.82M17.12M72.44M
Depreciation & Amortization2.41M2.36M2.22M2.16M2.5M
EBITDA(70.01M)(68.03M)(51.83M)(48.62M)(67.75M)
EBITDA Margin—-1728.7%-350.2%-178.0%-1896.2%
Operating Income(79.01M)(70.85M)(53.62M)(52.38M)(68.86M)
Operating Margin—-1800.4%-362.3%-191.8%-1927.3%
Interest Income6.49M69K1.04M3.2M1.87M
Interest Expense581K355K176K133K191K
Other Income / Expenses6.02M107K(599K)1.47M(1.58M)
Income Before Tax(72.99M)(70.74M)(54.22M)(50.91M)(70.45M)
Pre-Tax Margin—-1797.7%-366.3%-186.4%-1971.6%
Income Tax Expense3K13K10K3K0
Net Income(73M)(70.75M)(54.23M)(50.92M)(70.45M)
Net Margin—-1798.0%-366.4%-186.4%-1971.6%
EPS (Basic)(0.97)(0.85)(0.64)(0.51)(0.70)
EPS (Diluted)(0.97)(0.85)(0.64)(0.51)(0.70)
Weighted Avg Shares74.95M83.55M84.69M99.69M100.75M
Weighted Avg Shares (Diluted)74.95M83.55M84.69M99.69M100.75M

AC Immune S.A.

NASDAQ:ACIU

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.